

# The RECLAIM Study.

NCT06450444

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	Salvia BioElectronics
<b>Enrollment</b>	110 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Diagnosis of migraine as defined by the ICHD-3 Classification (with or without aura) with a history of chronic or high-frequency episodic migraine for at least 1 year prior to screening
- Failure of 3 or more preventive pharmacological therapies
- Stable on preventive migraine treatments
- Psychologically stable

### Exclusion (6)

- Concomitant invasive or non-invasive neuromodulation
  - Previous exposure to an implantable neuromodulation device for headache
  - Have an existing active implantable medical device nearby the implant location (e.g. DBS, cochlear implant)
  - Use of onabotulinum toxin A injections for the treatment of migraine in the past 3 months.
  - Use of local corticosteroid injections in the occipital or supra-orbital region in the past 3 months prior to enrollment.
- ... and 1 more (see full listing online)

## Locations (11 total)

---

Genesis Research Services, Broadmeadow, New South Wales, Australia  
Resolve Pain, Buderim, Queensland, Australia  
ZAS Antwerpen, Campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium  
... and 8 more locations